Summary
Fifty-eight patients with high-grade astrocytoma were treated by members of the Childrens Cancer Study Group in a prospective randomized trial designed to study the effectiveness of chemotherapy as an adjuvant to standard surgical treatment and radiotherapy. Following surgical therapy, patients were assigned randomly to radiotherapy with or without chemotherapy consisting of chloroethyl-cyclohexyl nitrosourea, vincristine, and prednisone. Treatment with chemotherapy prolonged survival and event-free survival. Five-year event-free survival was 46% for patients in the radiotherapy and chemotherapy group, and 18% for patients in the radiotherapy-alone group. Five-year survival was similarly improved. The differences in outcome due to treatment were statistically significant after correcting for imbalances in important prognostic factors (event-free survival, p = 0.026; survival, p = 0.067). The presence of mitoses or necrosis in the tumor specimen was associated with poorer outcome. Patients whose initial surgery was limited to biopsy, and patients with basal ganglia lesions, also had significantly worse outcome. Chemotherapy administered at the time of recurrence in a small number of patients did not produce any long-term survivors. This study is to our knowledge the only randomized trial to investigate effectiveness of chemotherapy in the treatment of high-grade astrocytoma in children.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cohen ME, Duffner PK, Tebbi CK: Brain Tumors in Children: Diagnosis and Management. In: Cameron K. Tebbi (ed) Major Topics in Pediatric and Adolescent Oncology. G.K. Hall and Co., Boston, 1982
McComb RD, Bigner DD: The biology of malignant gliomas — A comprehensive study. Clinical Neuropathology. 3: 93–106, 1984
Rubinstein LJ: Tumors of the Central Nervous System. In: Atlas of tumor pathology, Second series, Fascicle 6. Armed Forces Institute of Pathology, Washington D.C., 1972
Sheline GE: Radiation Therapy of Primary Tumors, Seminars in Oncology 64: 29–42, 1975
Walker MD: Tumors of the Central Nervous System. In: Arthur S. Levine (ed) Cancer in the Young. Masson Publishing, U.S.A., 1982
Chabner BA, Myers CE, Oliverio VT: Clinical pharmacology of anticancer drugs. Seminars in Oncology IV: 165–191, 1977
Cole WH: Chemotherapy of Cancer. Lea and Febiger, Philadelphia, 1970
Edwards MS, Levin VA, Wilson CB. Brain tumor chemotherapy: An evaluation of agents in current use for phase II and III trials. Cancer Treatment Reports 64: 1179–1205, 1980
Shapiro WR. Chemotherapy of primary malignant brain tumors in children. Cancer 35: 965–972, 1975
Kerhonan JW, Sayre GP: Tumors of the Central Nervous System. In: Atlas of Tumor Pathology, Section X, Fascicles 35 and 37. Armed Forces Institute of Pathology. Washington D.C., 1952
Nelson JS, Tsukada Y, Schoenfeld D, Fulling K, Lamarche J, Peress N: Necrosis as a Prognostic Criterion in Malignant Supratentorial, Astrocytic Gliomas. Cancer 52: 550–554, 1983
Fulling KA and Garcia DM. Anaplastic Astrocytoma of the Adult Cerebrum-Prognostic Value of Histologic Features. Cancer 55: 928–931, 1985
Pocock SJ, Simon R: Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial. Biometrics 31: 103–115, 1975
Byar DP, Simon RM, Friedewald WT, Schlesselman JJ, DeMets DL, Ellenberg JH, Gail MH, Ware JH: Randomized clinical trials: Perspectives on some recent ideas. N Engl J Med 295: 74–80, 1976
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part II: Analysis and examples. Br J Cancer 35: 1–39, 1977
Kalbfleisch JD and Prentice RL: The Statistical Analysis of Failure Time Data. John Wiley and Sons, New York, 1980
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part I: Introduction and design. Br J Cancer 34: 585–612, 1976
Simon R, Wittes RE: Methodologic guidelines for reports of clinical trials. Cancer Treatment Reports 69: 1–3, 1985
Burger PC, Vogel FS, Green SB, Strike TA: Glioblastoma Multiforme and Anaplastic Astrocytoma. Cancer 56: 1106–1111, 1985
Albright LA, Price RA, Guthkelch AN: Brain stem gliomas of children. Cancer 52: 2313–2319, 1983
Afra D, Kocsis B, Dobay J, Eckhardt S: Combined radiotherapy and chemotherapy with dibromudulcitol and CCNU in the postoperative treatment of malignant gliomas. J Neurosurg 59: 106–110, 1983
Chang CH, Horton H, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y: Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer 52: 997–1007, 1983
EORTC: Effect of CCNU on survival rate of objective remission and duration of free interval in patients with malignant brain glioma — final evaluation. Europ J Cancer 14: 851–856, 1978
EORTC: Evaluation of CCNU, VM-26 + CCNU, and procarbazine in supratentorial brain gliomas. J Neurosurg 55: 27–31, 1981
Green SB, Byar DP, Walker MD, Pistenmaa DA, Alexander E, Batzdorf U, Brooks WH, Hunt WE, Melaey J, Odom GL, Paoletti P, Ransohoff J, Robertson JT, Selker RG, Shapiro WR, Smith KR, Wilson CB, Strike TA: Comparisons of carmustine, procarbazine, and high-dose methyl prednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treatment Reports 67: 121–132, 1983
Hatlevoll R, Lindegaard K, Hagen S, Kristiansen K, Nesbakken R, Torvik A, Ganz JC, Mella O, Rosengren B, Ringkjob R, Arnasson O, Lindgren S, Lipechi M, Notter G, Littbrand B, Saterborg N, Benediktsson G, Johansson L, Spannare B, Brun A, Berthelsen A, Busch H, Gronbaek E, Rygard J, Haase JP, Lambrethsen E, Midholm S, Sehested P, Heikkinen M, Nystrom S, Taskinen P, Mantyla M, Elgen K, Aaskoven O, DeGaris ST, Jensen RH, Matheson I: Combined modality treatment of operated astrocytomas grade 3 and 4. Cancer 56: 41–47, 1985
Reagan TJ, Bisel HG, Childs DS, Layton DD, Rhoton AL, Taylor WF: Controlled study of CCNU and radiation therapy in malignant astrocytoma. J Neurosurg 44: 186–190, 1976
Walker MD, Alexander E, Hunt WW, MacCarty CS, Mahaley MS, Mealey J, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49: 333–343, 1978
Walker MD, Green SB, Byar DP, Alexander E, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, Owens G, Ransohoff J, Robertson JT, Shapiro WR, Smith KR, Wilcon CB, Strike TA: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323–1329, 1980
Stenning SP, Freedman LS, Bleehen NM: An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma. Br J Cancer 56: 89–90, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Spostol, R., Ertel, I.J., Jenkin, R.D.T. et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: Results of a randomized trial. J Neuro-Oncol 7, 165–177 (1989). https://doi.org/10.1007/BF00165101
Issue Date:
DOI: https://doi.org/10.1007/BF00165101